Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 1 August 2018, 18:35 HKT/SGT
Share:
Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA

Hangzhou and Shaoxing, China , Aug 1, 2018 - (ACN Newswire) - Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV) new drug application (NDA). Ravidasvir in combination with Ganovo (RDV/DNV Regimen) is the first all-oral interferon-free HCV regimen developed by a domestic company in China. Phase II/III clinical trial has shown that RDV/DNV Regimen demonstrated a cure rate of 99 % ( SVR12) with a short treatment duration of 12 weeks in genotype 1 patients. In patients with baseline NS5A resistance mutations, RDV/DNV Regimen demonstrated a cure rate of 100% (SVR12).

"Ascletis was successfully listed this morning on Hong Kong Exchange as the first ever pre-revenue biotech. The NDA for our all-oral HCV regimen was accepted by CFDA in the afternoon." Jinzi J. Wu, Ph.D., Ascletis' founder, President and CEO, commented, "Two significant accomplishments on the same day reflect our unremitting effort to provide affordable and effective HCV cures to the patients and to fulfill our commitment to the investors."

Ganovo Regimen, Ascletis' first breakthrough HCV regimen, was approved on June 8 and launched on June 27, 19 days after the approval. The acceptance of the NDA for its all-oral HCV regimen enables Ascletis soon to provide two HCV treatment options for Chinese patients, strengthening its leading position in China's HCV field.



Aug 1, 2018 18:35 HKT/SGT
Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
NEC Concludes 5th Multi-Vendor Wireless Transport SDN Proof of Concept with the Open Networking Foundation and ONAP  
Jan 22, 2019 17:18 HKT/SGT
NEC: Adoption of "Inter-AI Cooperative Fundamental Technology" in NEDO Business  
Jan 22, 2019 17:08 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fourth Time  
Jan 22, 2019 16:54 HKT/SGT
Fujitsu Develops AI Technology to Determine the Necessity of Cyberattack Responses  
Jan 22, 2019 16:42 HKT/SGT
Toyota and Panasonic Agree to Establish Joint Venture Related to Automotive Prismatic Batteries  
Jan 22, 2019 16:31 HKT/SGT
WARC Media Awards 2018: Effective Use of Tech winners announced  
Jan 22, 2019 16:30 HKT/SGT
Sanli has secured S$51.5 million worth of contracts from the Public Utilities Board (PUB)   
Jan 22, 2019 13:00 HKT/SGT
Ansaldo STS to Become Fully Owned by Hitachi and Delisted  
Jan 22, 2019 12:49 HKT/SGT
Fujitsu Launches 11 New Enterprise PC Models, Including Educational Tablet with Improved Ease of Use  
Jan 22, 2019 10:54 HKT/SGT
Fujitsu Group Earns Top Rating in CDP Climate Change Evaluation for Second Year Running  
Jan 22, 2019 10:42 HKT/SGT
More Press release >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: